99 results about "Tumor targeted" patented technology

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The application provides a preparation method of a Chlorella-arsene composite drug delivery system and application thereof. The application prepares arsene nanosheets (ANs) through a liquid phase stripping method, and obtains catechol-polyethyleneimine nanoparticles (CA-PEI) through oxidation self-polymerization. The ANs and the CA-PEI are charge-absorbed to form CA-PEI loaded with ANs (CA-PEI@ANs), and then charge-absorbed with protein nucleus Chlorella (CP), so that a Chlorella-arsene composite drug delivery system (CP@CA-PEI@ANs) is successfully constructed. The preparation operation of the drug delivery system is simple, and the reproducibility is good, and the drug delivery system has a good application prospect. The protein nucleus Chlorella is used as a drug delivery carrier, so that the problems of high cost and complex synthesis process commonly existing in a targeted delivery carrier are solved, and the application has good tumor targeting effect, and is beneficial to better drug efficacy.

The present application relates to the field of immunology, and particularly relates to a novel IL-15 fusion protein and application thereof. The present application provides an IL-15 transmembrane fusion protein, which is applied to NK cells or CAR-NK cells, can significantly enhance the tumor killing function of NK cells and CAR-NK cells, and can effectively promote the proliferation of NK cells and CAR-NK cells. It provides an important basis for developing NK cell products armored by the IL-15 transmembrane fusion protein, which are independent of any tumor target, thereby reducing the cycle and cost of CAR-NK development. Meanwhile, the present application respectively carries out function research in blood tumors expressing CD19 and solid tumors expressing CD276, and the results indicate the broad-spectrum application prospect of the structure in tumors.

This invention discloses a KK-LC-1 targeting binding protein and its derivatives, a kit, and applications. The protein sequence of the KK-LC-1 targeting binding protein is shown in one of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5. The KK-LC-1 targeting binding protein of this invention has a molecular weight of only about 17 kDa, approximately one-tenth that of an antibody, exhibiting good tissue penetration. Furthermore, its production process is simple and yields high quantities. The targeting binding protein of this invention demonstrates good targeting activity against KK-LC-1-positive tumors both in vivo and in vitro, and can be used for targeted tumor drug delivery, representing a potential drug for tumor immunotherapy. Simultaneously, a KK-LC-1 serum detection kit was developed using the targeting binding protein, enabling quantitative detection of KK-LC-1 levels in the human body.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.

The invention discloses a real-time positioning method for a tumor target region and a gold label implant, and belongs to the technical field of tumor localization, and the method specifically comprises the following steps: implanting a gold label in a tumor region, constructing a gold label-tumor dynamic model through CT, and obtaining a respiratory phase feature vector; realizing space matching of the two-dimensional projection and the three-dimensional model by using an improved hybrid registration algorithm, and obtaining a tumor compound displacement vector; establishing a respiration-displacement correlation model through time sequence alignment, generating a tumor movement map containing a real-time position and a predicted trajectory, and updating the reference coordinate system; establishing a rigid safety boundary based on a gold label, analyzing soft tissue texture and a prediction trajectory in combination with a convolutional neural network to generate an elastic treatment boundary, and dynamically adjusting a dose weight of a non-label area; and finally, submillimeter-level dynamic tracking is executed through a multi-leaf collimator. The problems of tumor motion uncertainty and individual deformation difference are solved, and the target area coverage precision and the dose distribution reasonability are improved.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The application belongs to the technical field of medicine preparation, and particularly relates to a magnetic layered double hydroxide, a targeted drug-loaded nano preparation, a preparation method and application of a tumor-targeted drug-loaded nano preparation. The preparation method of the magnetic layered double hydroxide provided by the application can prepare Fe3O4 nanoparticles with small particle size, and further prepare the magnetic layered double hydroxide which can be used as a water-soluble drug carrier. The magnetic layered double hydroxide is used for preparing the targeted drug-loaded nano preparation and the tumor-targeted drug-loaded nano preparation, and can be used for delivering water-soluble drugs such as 5-fluorouracil. The tumor-targeted drug-loaded nano preparation has good dispersity and can be actively targeted to HepG2 cells with high FR expression, has a good inhibitory effect on liver cancer cells, and is expected to provide a potential new treatment system for magnetic chemotherapy.

This invention discloses a method for esophageal cancer tumor target region segmentation based on cross-modal feature fusion of PET / CT images. The method uses a Transformer-fused Attention Progressive Semantic Nested Network (TransAttPSNN) as the 3D segmentation model for esophageal cancer tumor target regions. The TransAttPSNN network has an AttPSNN backbone structure and includes two segmentation networks: one for PET streams and the other for CT streams. Transformer cross-modal adaptive feature fusion modules are embedded in the different feature levels of the two segmentation networks. Compared with existing technologies, this invention effectively improves the segmentation accuracy of esophageal cancer tumor target regions and achieves better segmentation performance.

The invention provides a nano-drug system based on active drug self-assembly, a preparation method and application, CPT-C, MTX-C, ART and a lipid material are dispersed in an organic solvent, and a CMA (at) RGD-NPs nano-drug system is prepared through a film dispersion method. By constructing a nano drug delivery system with tumor targeting, ROS response release and multi-mode synergistic treatment, endogenous ferroptosis can be induced, and toxicity introduced by exogenous iron is avoided; a cGAS-STING pathway is activated, and natural and adaptive immunity is enhanced; and in combination with immunotherapy, a forward feedback loop is formed, and growth and transfer of TNBC are synergistically inhibited.

The invention relates to a multi-modal medical image deep learning enhanced segmentation system and a method thereof, belongs to the field of medical image processing, and aims to solve the problem of inaccurate brain glioma target region boundary segmentation. According to the technical scheme, the method comprises the steps that a metabolic domain PET image and a structural domain MRI-T2 image are obtained, and image registration, noise suppression and intensity standardization preprocessing are carried out; glycolysis features and texture anisotropy features are extracted through a double-domain feature decoupler; constructing a graph neural network to generate a metabolism-structure interaction graph; calculating a pathological infiltration confidence coefficient thermodynamic diagram based on the atlas; the thermodynamic diagram is used for self-adaptive radiotherapy dose segmentation, and the dose gradient is dynamically adjusted; and finally outputting the tumor target boundary.

The present disclosure provides novel radiopharmaceutical conjugates for tumor targeting and delivery, and their therapeutic and / or theragnostic use.

The invention belongs to the technical field of biological medicines, and particularly relates to sulfonium salt polypeptide or protein as well as a preparation method and application thereof. Polypeptide or protein containing cysteine and a sulfonium salt compound are used as raw materials, and the sulfonium salt compound is used for alkylation of cysteine at a specific site of the polypeptide or protein to prepare the sulfonium salt polypeptide or protein. The sulfonium salt polypeptide or protein is used as a probe for covalently labeling tryptophan in a lysine methylation reader protein recognition pocket. According to the method disclosed by the invention, different types of sulfonium salt polypeptides and protein probes can be simply, conveniently and efficiently prepared, and the designed annular sulfonium salt with a novel skeleton has an obvious improvement on the polypeptide or protein labeling yield of reader protein. The prepared sulfonium salt probe not only can be used for identifying lysine methylation modified reader protein and finding a therapeutic target for disease-related pathways, but also can be used for modifying tryptophan at a specific site of an antibody-coupled drug and provides a powerful tool for targeted therapy research of tumors.

The invention discloses a tumor treatment synergistic interaction system and method based on the acoustic cavitation effect of a phase-change nano-droplet. The system comprises the phase-change nano-droplet entrapped with a chemotherapeutic drug and a sound-sensitive agent and a cavitation effect intelligent monitoring and adjusting system. The method is characterized in that cavitation noise signals of a tumor target area are collected in real time through a cavitation monitoring system integrated in an ultrasonic probe, the inertial cavitation dosage is rapidly calculated through a signal processing system and compared with a preset threshold value, then a feedback instruction is generated to dynamically regulate and control ultrasonic irradiation parameters, and intelligent closed-loop control is formed. According to the method, the cavitation effect can be accurately maintained in an ideal treatment window, targeted release and deep penetration of the medicine and activation of the sound-sensitive agent are synchronously achieved through cavitation mechanical energy, and time-space synchronous synergistic interaction of chemotherapy and sonodynamic therapy is achieved.

The invention discloses a real-time image guiding method and system for organ motion compensation in tumor radiotherapy, and the method comprises the steps: constructing a respiratory motion model through the synchronous collection of the three-dimensional position of a gold mark and the motion track of a body surface LED mark point, and obtaining an atrophy compensation component through the combination of the volume atrophy proportion and the gravity center displacement of the gold mark in the radiotherapy process; and then carrying out weighted fusion on historical radiotherapy data, a gold label vector and a position relationship to obtain an accurate rotation compensation component, inputting the current position of the gold label into the model to update parameters in real time, predicting the position of the gold label at the next moment by combining the two types of compensation components, and meanwhile, carrying out model loop optimization through comparison of actual positions. According to the invention, the positioning accuracy of the target region in tumor radiotherapy is greatly improved, it is ensured that radioactive rays can accurately irradiate the tumor target region, the tumor local control rate is further improved, and the life quality of a patient is improved.

The invention belongs to the technical field of biological medicine, and particularly relates to a bionic photoactive nano preparation for tumor treatment as well as a preparation method and application thereof, and the preparation method comprises the following steps: synthesizing CaO2 (at) PDA-IR780 from nano calcium peroxide, polydopamine and iodide IR780, and synthesizing CaO2 (at) PDA-IR780 (at) M through a cell membrane coating technology. The obtained CaO2 (at) PDA-IR780 (at) M is a bionic photoactive nano preparation, the PDT effect of IR780 can be enhanced through in-situ oxygen production of nano calcium peroxide to improve the curative effect on tumors, controllable release of the preparation in the tumors is achieved through PDA acid response, and in-vivo long circulation and tumor targeted delivery are achieved through functional modification of nano particles through cell membranes. The photodynamic and photothermal activity is high, the tumor targeting characteristic and safety are good, and the application prospect in tumor treatment is wide.

Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula:or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection / imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

The invention discloses an intelligent delivery system and method for tumor targeted therapy based on stem cell exosomes. The system comprises engineered exosomes secreted by engineered stem cells, and the engineered stem cells over-express cell-penetrating peptide-nuclear localization signal peptide fusion protein; a chemotherapeutic drug and a prodrug with tumor microenvironment responsiveness are entrapped in the engineered exosome. Genetic engineering modification is performed on stem cells, so that cell-penetrating peptide-nuclear localization signal peptide fusion protein is displayed on an exosome membrane secreted by the stem cells. The fusion protein not only endows the exosome with efficient transmembrane ability, but also can guide the exosome to be further enriched to the nucleus after entering the tumor cell by virtue of the nuclear localization signal (NLS) characteristic of the fusion protein, so that dual active targeting of tissue targeting (tumor) and organelle targeting (nucleus) is realized, and the concentration of a drug at an action site is greatly improved.

The invention relates to a tumor target volume segmentation method and device and a storage medium. The method comprises the following steps: acquiring a medical image containing a target tumor; segmenting the target tumor in a spatial dimension according to the medical image to obtain a plurality of first target volumes which are located in the target tumor and are not overlapped; segmenting the plurality of first target volumes in a time dimension to obtain a plurality of target volume sets corresponding to different fractions; wherein the target volumes in the target volume set corresponding to at least one adjacent fraction are not completely the same. Through the tumor target volume segmentation method and device and the storage medium provided by the invention, accurate segmentation of the tumor target volume can be realized, and the pertinence of radiotherapy is improved, so that the damage to biological tissues around an irradiation area where a tumor is located in the radiotherapy process is reduced.

The invention discloses a charge-assisted targeting cyclodextrin carrier molecule as well as a preparation method and application thereof, the cyclodextrin carrier molecule integrates cyclodextrin, an M2pep ligand and a pH response group through chemical connection to obtain a biologically safe carrier with a clear structure and simple components. The carrier molecule is used for loading a drug and constructing nanoparticles, and cyclodextrin is responsible for loading a fluorescent dye or a nuclear drug; the M2pep ligand provides an active targeting function for the tumor; on one hand, the pH response group adjusts the surface charge of the nano-particles to enable the nano-particles to be negatively charged and prolong the blood circulation time of the medicine, and on the other hand, the nano-particles respond to an acidic tumor microenvironment and are switched into positive charges to enhance the tumor targeting of the nano-particles. In addition, the nano-particles also have the characteristics of quickly developing tumors, retaining in the tumors for a long time and quickly removing in normal organs, so that the technical problems of low tumor drug delivery efficiency and more non-target organ accumulation in the prior art are solved.

The present application belongs to the field of tumor treatment, and particularly relates to a multi-target ion and photon synchronous radiotherapy system, which comprises a rotating seat for driving the human body to rotate, an ion therapy module and a photon therapy module being arranged around the rotating seat; a release end of the ion therapy module is arranged towards the rotating seat, and the ion therapy module is used for outputting an ion beam to a drug-resistant tumor target area; meanwhile, a release end of the photon therapy module is arranged towards the rotating seat, and the photon therapy module is used for outputting a photon beam to a sensitive tumor target area; the rotating seat, the photon therapy module and the ion therapy module are respectively signal connected to a controller, and a treatment scheme planning module is signal connected to the controller. The present application provides a multi-target ion and photon synchronous radiotherapy system, and aims to solve the problem that the drug-resistant tumor area and the sensitive tumor area cannot be treated by the conventional means.

The application discloses a FLASH radiotherapy plan optimization method and system. In the FLASH radiotherapy system, a "FLASH effect index" is defined, the FLASH effect is quantified indirectly, and a basic index is provided for FLASH effect maximization; a FLASH biological database is designed according to X-ray and FLASH effect characteristics, which is beneficial to accurate calculation of FLASH effect equivalent photon dose and provides accurate data support for multi-target cooperation; through the design of "tumor target area weight + critical organ weight + FLASH effect weight" in the optimization process, the FLASH effect is maximized while tumor killing and critical organ dose control are ensured, and the defects of "trade-off" in the prior art are avoided.

Disclosed are a fusion protein, and a preparation method and use thereof, which belong to the field of biomedicine technologies. The fusion protein comprises a polypeptide specifically bound to a KRas protein, a specific tumor-cell-penetrating peptide and a lysosome recognition peptide. The fusion protein with tumor targeting, penetrability and specific protein degradation is designed and constructed direct to an undruggable protein for the first time, thus providing a new idea for development of an anti-cancer targeted drug. Different from the prior art in which one molecule can only target one target protein, the fusion protein can simultaneously induce degradation of wild-type and mutant-type KRas proteins. Meanwhile, the fusion protein can improve the sensitivity of the KRas mutant-type tumor to the tumor-targeted drug by inducing degradation of KRas, thus expanding an application range of existing anti-cancer targeted drugs and having important significance in tumor clinic treatment.

The invention relates to the technical field of biology, and discloses a method for discovering a new stomach-tumor target spot and a system establishment method. By integrating single cell second-generation sequencing and third-generation full-length transcriptome technologies and adopting a CopyKat and Infercnv dual algorithm model, the technical limitations that tumor heterogeneity cannot be analyzed by traditional batch sequencing and full-length new transcripts and malignant cells are difficult to accurately identify by conventional single cell sequencing are overcome. The method can systematically and precisely complete the whole process from cell subset analysis, malignant cell identification to brand new membrane protein target discovery, and further improves the reliability and transformation application potential of the discovered target through cross-platform verification and function correlation analysis, and has a wide application prospect. And a more efficient and reliable target spot discovery scheme is provided for gastric cancer targeted therapy and prognosis judgment.

This invention relates to a visualized boron drug-hyaluronic acid nanoparticle targeted delivery system, its preparation method, and its applications. After combining boron drug units and hyaluronic acid, a visualized drug is loaded using a hydrophilic-hydrophobic self-assembly effect, resulting in a visualized boron drug-hyaluronic acid nanoparticle targeted delivery system. The boron drug unit consists of a boron drug and a first active group at one end of a linker, both connected by covalent bonds. The linker is a hydrophobic chain compound with active groups at both ends. The boron drug unit and hyaluronic acid are bonded through the active group on the linker to the hydroxyl group on the hyaluronic acid. Compared with existing technologies, the boron drug-hyaluronic acid nanoparticle targeted delivery system provided by this invention not only possesses visualization imaging capabilities, the EPR effect of nanomedicines, and the tumor-targeting properties of hyaluronic acid, but also has advantages such as stable physicochemical properties, good biocompatibility, good dispersibility, and in vivo degradability. It shows great promise for application in boron neutron capture therapy for tumors.

The invention discloses a photodynamic-immune synergistic treatment composition for triple negative breast cancer and application of the photodynamic-immune synergistic treatment composition, and relates to the technical field of tumor treatment and nano-drug delivery. The invention provides a multifunctional integrated nano-particle delivery system which is used for realizing collaborative regulation and control of ER targeted photodynamic therapy and IDO-1 pathway inhibition. The composition comprises the following functional components: an ER targeting photosensitive component; an immunosuppressive pathway modulating component; a tumor targeting nano-carrier; the components can form stable and dispersed nanoparticles in a self-assembly or entrapment manner, so that the water-phase dispersibility and in-vivo stability of the hydrophobic drug are improved, and coordinated delivery and synergistic release of the two active components at a tumor site are realized. Through the active targeting effect mediated by the tumor targeting carrier and the passive enrichment effect of the tumor tissue, the distribution and retention of the active component in the tumor tissue are improved, and the non-target tissue exposure is reduced.

This invention provides a compound targeting FAPI, its composition, and its applications, relating to the fields of radiopharmaceutical chemistry and clinical nuclear medicine. The structure of the compound is shown in formula (I). The compound of formula (I) provided by this invention, or its isomers or pharmaceutically acceptable salts, can reversibly bind to TTR in the blood, prolonging the circulation time of FAPI in the blood, thereby improving the uptake of the compound at the tumor target site and enhancing imaging effects. After radionuclide labeling, the resulting radioactive agent exhibits high uptake in tumor tissue, a favorable tumor / non-target ratio, and good tumor uptake performance, demonstrating promising practical application prospects. (I)